Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 3
1971 1
1975 2
1977 2
1979 1
1980 1
1981 1
1982 3
1983 4
1985 2
1986 2
1987 1
1990 3
1991 1
1992 2
1993 4
1994 5
1995 9
1996 2
1997 5
1998 7
1999 2
2000 5
2001 7
2002 5
2003 6
2004 3
2005 2
2006 5
2007 8
2008 14
2009 13
2010 25
2011 21
2012 16
2013 25
2014 34
2015 31
2016 35
2017 32
2018 32
2019 23
2020 28
2021 38
2022 33
2023 23
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

468 results

Results by year

Filters applied: . Clear all
Page 1
Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration.
Tusch E, Ryom L, Pelchen-Matthews A, Mocroft A, Elbirt D, Oprea C, Günthard HF, Staehelin C, Zangerle R, Suarez I, Vehreschild JJ, Wit F, Menozzi M, d'Arminio Monforte A, Spagnuolo V, Pradier C, Carlander C, Suanzes P, Wasmuth JC, Carr A, Petoumenos K, Borgans F, Bonnet F, De Wit S, El-Sadr W, Neesgaard B, Jaschinski N, Greenberg L, Hosein SR, Gallant J, Vannappagari V, Young L, Sabin C, Lundgren J, Peters L, Reekie J; D:A:D cohort study; RESPOND cohort study. Tusch E, et al. Clin Infect Dis. 2024 Apr 26:ciae228. doi: 10.1093/cid/ciae228. Online ahead of print. Clin Infect Dis. 2024. PMID: 38663013
Plain Language Summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma.
Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Rodriguez-Otero P, et al. Among authors: delforge m. Future Oncol. 2024 Apr 23. doi: 10.2217/fon-2023-0954. Online ahead of print. Future Oncol. 2024. PMID: 38651976 Free article. Review.
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, Marshall TS, Arnulf B, Cavo M, Nooka A, Manier S, Callander N, Giralt S, Einsele H, Ailawadhi S, Popa McKiver M, Cook M, Rodríguez-Otero P. Delforge M, et al. Lancet Haematol. 2024 Mar;11(3):e216-e227. doi: 10.1016/S2352-3026(24)00005-X. Lancet Haematol. 2024. PMID: 38423700 Clinical Trial.
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma.
Mateos MV, Weisel K, Terpos E, Delimpasi S, Kastritis E, Zamagni E, Delforge M, Ocio E, Katodritou E, Gay F, Larocca A, Leleu X, Otero PR, Schjesvold F, Cavo M, Dimopoulos MA. Mateos MV, et al. Among authors: delforge m. Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284694. Online ahead of print. Haematologica. 2024. PMID: 38385280 Free article.
Nationwide quality assurance of high-throughput diagnostic molecular testing during the SARS-CoV-2 pandemic: role of the Belgian National Reference Centre.
Janssen R, Cuypers L, Laenen L, Keyaerts E, Beuselinck K, Janssenswillen S, Slechten B, Bode J, Wollants E, Van Laethem K, Rector A, Bloemen M, Sijmons A, de Schaetzen N, Capron A, Van Baelen K, Pascal T, Vermeiren C, Bureau F, Vandesompele J, De Smet P, Uten W, Malonne H, Kerkhofs P, De Cock J, Matheeussen V, Verhasselt B, Gillet L, Detry G, Bearzatto B, Degosserie J, Henin C, Pairoux G; COVID-19 Genomics Belgium Consortium; Maes P, Van Ranst M, Lagrou K, Dequeker E, André E. Janssen R, et al. Virol J. 2024 Feb 10;21(1):40. doi: 10.1186/s12985-024-02308-y. Virol J. 2024. PMID: 38341597 Free PMC article. Review.
Proliferative glomerulonephritis with monoclonal immunoglobulin deposits in the native or posttransplant kidney.
Verbinnen M, Sprangers B, Abrahams AC, Koshy P, Van Kruijsdijk RCM, Philipse E, Michalak M, Delforge M, Vos JMI, Wetzels J, Dendooven A, Van Craenenbroeck AH. Verbinnen M, et al. Among authors: delforge m. Nephrol Dial Transplant. 2024 Apr 26;39(5):888-892. doi: 10.1093/ndt/gfae005. Nephrol Dial Transplant. 2024. PMID: 38192041 No abstract available.
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
Moreau P, Mateos MV, Gonzalez Garcia ME, Einsele H, De Stefano V, Karlin L, Lindsey-Hill J, Besemer B, Vincent L, Kirkpatrick S, Delforge M, Perrot A, van de Donk NWCJ, Pawlyn C, Manier S, Leleu X, Martinez-Lopez J, Ghilotti F, Diels J, Morano R, Albrecht C, Strulev V, Haddad I, Pei L, Kobos R, Smit J, Slavcev M, Marshall A, Weisel K. Moreau P, et al. Among authors: delforge m. Adv Ther. 2024 Feb;41(2):696-715. doi: 10.1007/s12325-023-02738-0. Epub 2023 Dec 19. Adv Ther. 2024. PMID: 38110653 Free PMC article.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P; PERSEUS Trial Investigators. Sonneveld P, et al. Among authors: delforge m. N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12. N Engl J Med. 2024. PMID: 38084760 Clinical Trial.
468 results